Real World Evidence Solutions Market in Healthcare IT Industry at a CAGR of 14.3% | Global Forecast To 2023
According to the latest research report ” Real World Evidence Solutions Market by Component (Dataset (Claims, Clinical, Pharmacy, Patient), Services), Therapeutic Area (Oncology, Cardiovascular, Immunology), End User (Pharmaceuticals, Medical Devices, Payers, Providers) – Global Forecast to 2023 ”
The global real-world evidence market is valued at 612.0 million in 2017 and projected to reach USD 1,348.1 million by 2023, at a CAGR of 14.3%.
Download a FREE Pdf Brochure @:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991
The growth of this market is majorly driven by the rising geriatric population (and the subsequent increase in the prevalence of chronic diseases), shift from volume- to value-based care, and delays in drug development (and the subsequent increase in development costs).
The base year considered for the study is 2017 and the forecast period includes 2018 to 2023.
The prominent players in the global real world evidence market are:
IQVIA (US), International Business Machines Corporation (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), Optum (US), Cognizant (US), Oracle (US), SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US).
Scope of the Report:-
- Based on Component
- Based on Therapeutic Area
- Based on End User
- Based on Region
Based on end user, the real-world evidence market is segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and other end users (academic institutions, patient advocacy groups, and health technology assessment agencies).
The pharmaceutical & medical device companies segment accounted for the largest share of the market in 2017. The large share of this segment can be attributed to the increasing importance of RWE studies in drug approvals, the need to prevent costly drug recalls, and the increasing need to assess drug performance in real-world settings.
The real-world evidence market is broadly segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW).
In 2017, North America accounted for the largest share of the market, followed by Europe and Asia Pacific. Presence of a favorable regulatory environment, high number of RWE service providers, the presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure, are the major factors responsible for the large share of North America in the global real world evidence market.
Get Sample Report with all Graphs & Charts related to it @: https://www.marketsandmarkets.com/requestsampleNew.asp?id=76173991
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: 1-888-600-6441
Email: sales@marketsandmarkets.com
